Current management gestational diabetes mellitus

Expert Review of Obstetrics and Gynecology

Volumn 3, Issue 1, 2008, Pages 73-91

  Menato, Guido ^a   Bo, Simona ^b   Signorile, Anna ^a   Gallo, Marie Laure ^a   Cotrino, Ilenia ^a   Poala, Chiara Botto ^a   Massobrio, Marco ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Blood glucose monitoring; Diet; Gestational diabetes mellitus; Insulin analogues; Oral antidiabetic agents; Physical activity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ABSENCE OF SIDE EFFECTS; AGE; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; CARBOHYDRATE INTOLERANCE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGENITAL MALFORMATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIET THERAPY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MILK LEVEL; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; EMBRYOTOXICITY; ETHNICITY; EXERCISE; FAT INTAKE; FEMALE; FOOD; FOOD DRUG INTERACTION; GASTRITIS; GLYCEMIC CONTROL; GOLD STANDARD; HEREDITY; HUMAN; HYPOGLYCEMIA; IMMUNOGENICITY; INSULIN TREATMENT; INTRAPARTUM CARE; INTRAUTERINE GROWTH RETARDATION; LACTIC ACIDOSIS; META ANALYSIS; METABOLIC REGULATION; MORNING DOSAGE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PARITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PRENATAL CARE; PREVALENCE; PUERPERIUM; RETINOPATHY; REVIEW; RISK FACTOR; RISK REDUCTION; SHORT STATURE; SMOKING; SYSTEMATIC REVIEW; TERATOGENICITY; TREATMENT INDICATION;

EID: 38949163993     PISSN: 17474108     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474108.3.1.73     Document Type: Review

References (147)

1. Langer O. Management of gestational diabetes: pharmacologic treatment options and glycemic control. Endocrinol. Metab. Clin. North Am. 35, 53-78 (2006).
2. Langer O. When diet fails: insulin and oral hypoglycaemic agents as alternatives for management of gestational diabetes mellitus. J. Matern. Fetal Med. 11, 218-225 (2002).
3. Bo S, Menato G, Lezo A et al. Dietary fat and gestational hyperglycaemia. Diabetologia 44, 972-978 (2001).
4. Hollander MH, Paarlberg KM, Huisjes AJM. Gestational diabetes: a review of the current literature and guidelines. Obstet. Gynecol. Survey 62 (2), 125-136 (2007).
5. American Diabetes Association. Position statement. Gestational diabetes mellitus. Diabetes Care 29(Suppl.) (2006).
6. Brody SC, Harris R, Lohr K. Screening for gestational diabetes: a summary of the evidence for the U.S. Preventive Service Task Force. Obstet. Gynecol. 101, 380-392 (2003).
7. Berger H, Crane J, Farine D. Screening for gestational diabetes mellitus. J. Obstet. Gynaecol. Can. 24, 894-912 (2002).
8. O'Sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test in pregnancy. Diabetes 13, 278-285 (1964).
9. Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop Conference on Gestational Diabetes. The Organizing Committee. Diabetes Care 21 (Suppl. 2), B161-B167 (1998).
10. American College of Obstetricians and Gynecologists Committee on Practice Bulletin - Obstetrics. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001. Gestational diabetes. Obstet. Gynecol. 98(3), 525-538 (2001).
11. American Diabetes Association. Position statement on gestational diabetes mellitus. Diabetes Care 27(Suppl. 1), S88-S90 (2004).
12. Major CA, Henry MJ, De Veciana M, Morgan MA. The effects of carbohydrate restriction in patients with diet-controlled gestational diabetes. Obstet. Gynecol. 91(4), 600-604 (1998).
13. Nutritional management during pregnancy in pre-existing diabetes. In: American Diabetes Association Medical Management of Pregnancy Complicated by Diabetes (3rd Edition). ADA, VA, USA, 70-86 (2000).
14. Metzger BE, Buchanan TA, Coustan DR et al. Summary and Reccomendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 30, S251-S260 (2007).
15. Gabbe SG, Graves CR. Management of diabetes mellitus complicating pregnancy. Obstet. Gynecol. 102(4), 857-868 (2003).
16. Rizzo T, Metzger BE, Burns K. Correlations between antepartum maternal metabolism and child intelligence. N. Engl. J. Med. 325, 911-916 (1991).
17. Rizzo TA, Dooley SL, Metzger BE, Cho NH, Ogata ES, Silverman BL. Prenatal and perinatal influences on long-term psychomotor development in offspring of diabetic mothers. Am. J. Obstet. Gynecol. 173(6), 1753-1758 (1995).
18. Algert S, Shragg P, Hollingsworth DR. Moderate caloric restriction in obese women with gestational diabetes. Obstet. Gynecol. 65, 487-491 (Level 11-2) (1985).
19. Dyck R, Klomp H, Tan LK, Turnell RW, Boctor MA. A comparison of rates, risk factors, and outcomes of gestational diabetes between aboriginal and non-aboriginal women in the Saskatoon health district. Diabetes Care 25(25), 487-493 (2002).
20. Dempsey JC, Butler CL, Sorensen TK et al. A case-control study of maternal recreational physical activity and risk of gestational diabetes mellitus. Diabetes Res. Clin. Pract. 66(2), 203-215 (2004).
21. Dempsey JC, Sorensen TK, Williams MA et al. Prospective study of gestational diabetes mellitus risk in relation to maternal recreational physical activity before and during pregnancy. Am. J. Epidemiol. 159(7), 663-670 (2004).
22. Zhang C, Solomon CG, Manson JE, Hu FB. A prospective study of pregravid physical activity and sedentary behaviors in relation to the risk for gestational diabetes mellitus. Arch. Intern. Med. 166, 543-548 (2006).
23. Jovanovic-Peterson L, Peterson CM. Exercise and the nutritional management of diabetes during pregnancy. Obstet. Gynecol. Clin. North. Am. 23, 75-86 (1996).
24. Bung P, Artal R. Gestational diabetes and exercise: a survey. Semin. Perinatol. 20, 328-333 (1996).
25. Artal R. Exercise: the alternative therapeutic intervention for gestational diabetes. Clin. Obstet. Gynecol. 46(2), 479-487 (2003).
26. Artal R, Bellman O, Dekets T et al. Summary and recommendations of the Second International Workshop-Conference on Gestational Diabetes Mellitus: therapeutic strategies. Diabetes 34, 125 (1985).
27. Jovanovic-Peterson L, Durak EP, Peterson CM. Randomized trial of diet vs diet plus cardiovascular conditioning on glucose levels in gestational diabetes. Am. J. Obstet. Gynecol. 161, 415-419 (1989).
28. Avery MD, Leon AS, Kopher RA. Effects of a partially home-based exercise program for women with gestational diabetes. Obstet. Gynecol. 89, 10-15 (1997).
29. American College of Obstetricians and Gynecologists Committee Opinion. Exercise during pregnancy and the postpartum period. 99(1), 171-173 (2002).
30. Brankston GN, Mitchell BF, Ryan EA, Okun NB. Resistance exercise decreases the need for insulin in overweight women with gestational diabetes mellitus. Am. J. Obstet. Gynecol. 190, 188-193 (2004).
31. Ceysens G, Rouiller D, Boulvain M. Exercise for diabetic pregnant women. Cochrane Database Syst. Rev. 3, CD004225 (2006).
32. [no author listed] Impact of physical activity during pregnancy and postpartum on chronic disease risk. Med. Sci. Sports Exerc. 38(5), 989-1006 (2006).
33. Artal R, O'Toole M. Guidelines of the American College of Obstetricians and Gynecologists for exercise during pregnancy and the postpartum period. Br. J. Sports Med. 37(1), 6-12 (2003).
34. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complication. Diabetes Care 26 (Suppl. I), S51-S61 (2003).
35. Turok DK, Ratcliffe SD, Baxley EG. Management of gestational diabetes mellitus. Am. Fam. Physician 68, 1767-1772 (2003).
36. Lindsay MK, Graves W, Klein L. The relationship of one abnormal glucose tolerance test value and pregnancy complications. Obstet. Gynecol. 73, 103-106 (1989).
37. ACOG Practice Bulletin Clinical Management Guidelines for Obstetrician-Gynecologists No.30. Obstet. Gynecol. 98(3), 525-538 (2001).
38. De Veciana M, Major CA, Morgan MA et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N. Engl. J. Med. 333, 1237-1241 (1995).
39. Chen R, Yogev Y, Ben-Haroush A et al. Continuous glucose monitoring for the evaluation and improved control of gestational diabetes mellitus. J. Matern. Fetal Med. 14, 256-260 (2003).
40. McLachlan K, Jenkins A, O'Neal D. The role of continuous glucose monitoring in clinical decision-making in diabetes in pregnancy. Aust. N. Z. J. Obstet. Gynaecol. 47(3), 186-190 (2007).
41. Kestilä KK, Ekblad UU, Rönnemaa T. Continuous glucose monitoring versus self-monitoring of blood glucose in the treatment of gestational diabetes mellitus. Diabetes Res. Clin. Pract. 77(2), 174-179 (2007).
42. Genuth SM, Gebhart SSP, Friedman EA et al. Special situation. In: The CADRE Handbook of Diabetes Management. Cefalu WT, Gerich JE, LeRoith D (Eds). Medical Information Press, NY, USA (2004).
43. Buchanan TA, Kjos SL, Montoro MN et al. Use of fetal ultrasounds to select metabolic therapy for pregnancies complicated by mild gestational diabetes. Diabetes Care 17, 275-283 (1994).
44. Bühling KJ, Winkel T, Wolf C et al. Optimal timing for postprandial glucose measurement in pregnant women with diabetes and a non-diabetic pregnant population evaluated by the Continuous Glucose Monitoring System. J. Perinat. Med. 33, 125-131 (2005).
45. Parretti E, Mecacci F, Papini M et al. Third-trimester maternal glucose levels from diurnal profiles in nondiabetic pregnancies. Diabetes Care 24, 1319-1323 (2001).
46. Yogev Y, Ben-Haroush A, Chen R et al. Diurnal glycemic profile in obese and normal weight nondiabetic pregnant women. Am. J. Obstet. Gynecol. 191, 1655-1660 (2004).
47. McFarland MB, Langer O, Conway DL et al. Dietary therapy for gestational diabetes: how long is long enough? Obstet. Gynecol. 93, 978-982 (1999).
48. Hirsch IB. Insulin Analogues. N. Eng. J. Med. 352 (2), 174-183 (2005).
49. Lapolla A, Dalfra MG, Fedele D. Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool? Diabetes Metab. Res. Rev. 21(3),241-252 (2005).
50. Holcberg G, Tsadkin-Tamir M, Sapir O et al. Transfer of insulin lispro across the human placenta. Eur. J. Obstet. Gynecol. Reprod. Biol. 115(1), 117-118 (2004).
51. Mathiesen ER, Kinsley B, Amiel SA et al. Insulin Aspart Pregnancy Study Group. Maternal glycemic control and hypoglycemia in Type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 30(4), 771-776 (2007).
52. Owens D, Vora J. Insulin aspart: a review. Expert Opin. Drug Metab. Toxicol. 2(5), 793-804 (2006).
53. Garg SK, Ellis SL, Ulrich H. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin. Pharmacother. 6, 643-651 (2005).
54. Bolli GB, Owens DR. Insulin glargine. Lancet 356(9228), 443-445 (2000).
55. Hofmann T, Horstmann G, Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int. J. Toxicol. 21(3), 181-189 (2002).
56. Hussar DA. New drugs 07, part I. Nursing 37(2), 51-58 (2007).
57. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with Type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26(3), 590-596 (2003).
58. Bott S, Tusek C, Jacobsen LV, Kristensen A, Heise T. Insulin detemir reaches steady-state after the first day of treatment and shows a peakless time-action profile with twice-daily applications. In: International Diabetes Federation Abstract Volume of the 18th Congress. Paris, France (2003).
59. Langer O, Anyaegbunam A, Brustman L. Pregestational diabetes: insulin requirements throughout pregnancy. Am. J. Obstet. Gynecol. 159, 616-662 (1988).
60. DeWitt DE, Hirsch IB. Outpatient insulin therapy in Type 1 and Type 2 diabetes mellitus. JAMA 289, 2254-2264 (2003).
61. Farrar D, Tuffnell Dj, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst. Rev. 18(3) (2007).
62. Mukhopadhyay A, Farrell T, Fraser RB. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am. J. Obstet. Gynecol. 3 (2007) (Epub ahead of print).
63. Langer O. Oral hypoglycaemic agents in pregnancy: their time has come. J. Matern. Fetal Med. 12, 376-383 (2002).
64. De Veciana M. A comparison of oral acarbose and insulin in women with Gestational Diabetes Mellitus. Obstet. Gynecol. 99, 5S (2002).
65. Zarate A, Ochoa R, Hernandez et al. Effectiveness of acarbose in the control of glucose tolerance worsening in pregnancy. Ginecol. Obstet. Mex. 68, 42-45 (2000).
66. Langet O, Conway DL, Berkus MD. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N. Engl. J. Med. 343, 1134-1138 (2000).
67. Feig OS, Briggs GG, Kmenser JM. Transfer of glyburide and glipzide into breast milk. Diabetes Care 28, 1851-1855 (2005).
68. Langer O, Yogev Y, Xenakis EMG. Insulin and glyburide therapy: dosage, severity level of gestational diabetes and pregnancy outcome. Am. J. Obstet. Gynecol. 192, 134-139 (2004).
69. Yogev Y, Ben-Haroush A, Chen R. Undiagnosed asymptomatic hypoglycaemia: diet, insulin and glyburide for gestational diabetic pregnancy. Obstet. Gynecol. 104, 88-93 (2004).
70. Jacobson GF, Ramos GA, Ching JY et al. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am. J. Obstet. Gynecol. 193, 118-124 (2005).
71. Homko CJ, Reece EA. Insulins and oral hypoglycaemic agents in pregnancy. J. Matern. Fetal Med. 19(11), 679-686 (2006).
72. Hawthorne G. Merformin use and diabetic pregnancy- has its time come? Diabetic Med. 23, 223-227 (2006).
73. Goetzel I, Wilkins I. Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis. J. Perinatol. 22, 403-406 (2002).
74. Gilbert C, Valois M, Koren C. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fert. Steril. 86(3), 658-663 (2006).
75. McCarthy EA, Walker SP, McLachlan K et al. Metformin in obstetric and gynaecologic practice: a review. Obstet. Gynecol. Surv. 59(2), 118-127 (2004).
76. Gardiner SJ, Kirkpatrick CM, Begg EJ et al. Transfer of metformin into human milk. Clin. Pharmacol. Ther. 73, 71-77 (2003).
77. Checa MA, Requena A, Salvador C et al. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary sindrome. Hum. Reprod. Update 11(4), 375-390 (2005).
78. Norman RJ, Wang JX, Hague W. Should we continue or stop insulin sensitizing drugs during pregnancy? Curr. Opin. Obstet. Gynecol. 16, 245-250 (2004).
79. Glueck CJ, Wang P, Kobayashi S et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil. Steril. 77(3), 520-525 (2002).
80. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycistic ovary syndrome treated with metformin. Hum. Reprod. 17(11), 2858-2864 (2002).
81. Jakubowicz DJ, Iuorno MJ, Jakubowicz S et al. effects of metformin on early pregnancy, loss in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87, 524-529 (2002).
82. Glueck CJ, Goldenberg N, Pranikoff J et al. Height, weight and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum. Reprod. 19(6), 1323-1330 (2004).
83. Vanky E, Salvesen KA, Heimstad R et al. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum. Reprod. 19(8), 1734-1740 (2004).
84. Reece EA, Homko CJ. Metformin in pregnancy: ready or not. Curr. Opin. Endocrinol. Diabetes 13, 185-190 (2006).
85. Hague WM, Davoren PM, Oliver D, Rowan J. Metformin may be useful in gestational diabetes. BMJ 326, 762-763 (2003).
86. Hughes RCE, Rowan JA. Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? Diabet. Med. 23, 318-322 (2006).
87. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet. Med. 17, 507-511 (2000).
88. Glueck CJ, Bornovali S, Pranikoff J et al. Metformin, pre-eclampsia and pregnancy outcomes in women with polycystic ovary syndrome. Diabet. Med. 21, 829-836 (2004).
89. Gabbe SC, Mestman JH, Freeman RK et al. Management and outcome of Class A diabetes mellitus. Am. J. Obstet. Gynecol. 127, 465-469 (1977).
90. Crowther CA, Hiller JE, Moss JR. Effect of the treatment of gestational diabetes mellitus on pregnancy outcomes. N. Engl. J. Med. 352(24), 2477-2486 (2005).
91. Evans E, Patry R. Management of gestational diabetes mellitus and pharmacists'role in patient education. Am. J. Health Syst. Pharm. 61, 1460-1465 (2004).
92. Jensen D, Sorensen B, Feilberg-Jorgensen N et al. Maternal and perinatal outcomes in 143 Danish women with gestational diabetes mellitus and 143 controls with a similar risk profile. Diabet. Med. 17, 281-286 (2000).
93. Casey B, Lucas M, McIntire D et al. Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population. Obstet. Gynecol. 90, 869-873 (1997).
94. Boulet SL, Salihu HM, Alexander GR. Mode of delivery and birth outcomes of macrosomic infants. J. Obstet. Gynaecol. 24 (6), 622-629 (2004).
95. Acker DB, Sachs BP, Friedman EA. Risk factors for shoulder dystocia. Obstet. Gynecol. 66, 762-768 (1985).
96. Major C, deVeciana M, Weeks J et al. Recurrence of gestational diabetes: who is at risk? Am. J. Obstet. Gynecol. 179, 1038-1042 (1998).
97. Nahum GG, Stanislaw H. Ultrasonographic prediction of term birth weigh: how accurate is it? Am. J. Obstet. Gynecol. 188, 566-574 (2003).
98. Herbst MA. Treatment of suspected fetal macrosomsa: a cost-effectiveness analysis. Am. J. Obstet. Gynecol. 193(Suppl. 1), 1035-1039 (2005).
99. Kjos SL, Henry OA, Montoro M et al. Insulin-requiring diabetes in pregnacy: a randomized trial of active induction of labor and expectant management. Am. J. Obstet. Gynecol. 169, 611-615 (1993).
100. Lurie S, Insler V, Hagay ZJ. Induction of labor at 38 to 39 weeks of gestation reduces the incidence of shoulder dystocia in gestational diabetic patients Class A2. Am. J. Perinatol. 13, 293-296 (1996).
101. Irion O, Bouvain M. Induction of labor for suspected fetal macrosomia. The Cochrane Library Issue 2 (2004).
102. Rayburn WF, Sokkary N, Clokey DE et al. Consequences of routine delivery at 38 weeks for A-2 gestational diabetes. J. Matern. Fetal Med. 18(5), 333-337 (2005).
103. Peled Y, Perri T, Cen R et al. Gestational diabetes mellitus - implications of different treatment protocols. J. Pediatr. Endocrinol. Metab. 17(6), 847-852 (2004).
104. Tuffnell DJ, West J, Walkinshaw SA. Treatments for gestational diabetes and impaired glucose tolerance in pregnancy. Cochrane Database Syst. Rev. 2, CD003395 (2005).
105. Berger H, Crane J, Farine D. Screening for gestational diabetes mellitus. J. Obstet. Gynaecol. Can. 24, 894-912 (2002).
106. Haeusler MC, Konstantiniuk P, Dorfer M, Weiss PA. Amniotic fluid insulin testing in gestational diabetes: safety and acceptance of amniocentesis. Am. J. Obstet. Gynecol. 179(4), 917-920 (1998).
107. Fraser RB, Bruce C. Amniotic fluid insulin levels identify the fetus at risk of neonatal hypoglycaemia. Diabet. Med. 16(7), 568-572 (1999).
108. Caplan RH, Pagliara AS, Beguin EA et al. Constant intravenous insulin infusion during labor and delivery in diabetes mellitus. Diabetes Care 5, 6-10 (1982).
109. Golde SH, Good-Anderson B, Montoro M. Insulin requirements during labour: a reappraisal. Am. J. Obstet. Gynecol. 144, 556-559 (1982).
110. Jovanovic L. Glucose and insulin requirements during labour and delivery: the case for normoglycemia in pregnancies complicated by diabetes. Endocr. Pract. 10(Suppl. 2), 40-45 (2004).
111. Rosenberg VA, Eglinton CS, Rauch ER. Intrapartum maternal glycemic control in women with insulin requiring diabetes: a randomized clinical trial of rotating fluids versus insulin drip. Am. J. Obstet. Gynecol. 195, 1095-1099 (2006).
112. Kim C, Herman WH, Vijan S. Efficacy and cost of postpartum screening strategies for diabetes among women with histories of gestational diabetes mellitus. Diabetes Care 30(5), 1102-1106 (2007).
113. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of Type 2 diabetes: a systematic review. Diabetes Care 25, 1862-1868 (2002).
114. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am. J. Obstet. Gynecol. 144, 768-773 (1982).
115. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28, 1039-1057 (1979).
116. Alberti KGMM, Zimmet PZ; for the WHO Consultation. Definition, diagnosis and classification of diabetes mellirus and its complications, Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet. Med. 15, 539-553 (1998).
117. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 26(Suppl. 1), S103-S105 (2003).
118. Meltzer S, Leiter L, Daneman D et al. 1998 clinical practice guidelines for the management of diabetes in Canada. CMAJ 159(Suppl. 8), S1-S29 (1998).
119. Jovanovic L, Ilic S, Pettitt DJ, Hugo K et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 22(9), 1422-1427 (1999).
120. Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care 26(5), 1390-1394 (2003).
121. Diamond T, Kormas N. Possible adverse fetal effect of insulin lispro. N. Engl. J. Med. 337(14), 1009; author reply 1010 (1997).
122. Buchbinder A, Miodovnik M, McElvy S et al. Is insulin lispro associated with the development or progression of diabetic retinopathy during pregnancy? Am. J. Obstet. Gynecol. 183(5), 1162-1165 (2000).
123. Idama TO, Lindow SW, French M, Masson EA. Preliminary experience with the use of insulin lispro in pregnant diabetic women. J. Obstet. Gynaecol. 21(4), 350-351 (2001).
124. Bhattacharyya A, Brown S, Hughes S, Vice PA. Insulin lispro and regular insulin in pregnancy. QJM 94(5), 255-260 (2001).
125. Persson B, Swahn ML, Hjertberg R et al. Insulin lispro therapy in pregnancies complicated by Type 1 diabetes mellitus. Diabetes Res. Clin. Pract. 58(2), 115-121 (2002).
126. Garg SK, Frias JP, Anil S, Gottlieb PA, MacKenzie T, Jackson WE. Insulin lispro therapy in pregnancies complicated by Type 1 diabetes: glycemic control and maternal and fetal outcomes. Endocr. Pract. 9(3), 187-193 (2003).
127. Masson EA, Patmore JE, Brash PD et al. Pregnancy outcome in Type I diabetes mellitus treated with insulin lispro (Humalog). Diabet. Med. 20(1), 46-50 (2003).
128. Cypryk K, Sobczak M, Pertynska-Marczewska M et al. Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy. Med. Sci. Monit. 10(2), PI29-PI32 (2004).
129. Wyatt JW, Frias JL, Hoyme HE et al. IONS study group. Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet. Med. 22(6), 803-807 (2005).
130. Kitzmiller JL, Main E, Ward B, Theiss T, Peterson DL. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care 22(5), 874-876 (1999).
131. Bhattacharyya A, Vice PA. Insulin lispro, pregnancy, and retinopathy. Diabetes Care 22(12), 2101-2104 (1999).
132. Loukovaara S, Immonen I, Teramo KA, Kaaja R. Progression of retinopathy during pregnancy in Type 1 diabetic women treated with insulin lispro. Diabetes Care 26(4), 1193-1198 (2003).
133. Carr KJ, Idama TO, Masson EA, Ellis K, Lindow SW. A randomised controlled trial of insulin lispro given before or after meals in pregnant women with Type 1 diabetes-the effect on glycaemic excursion. J. Obstet. Gynaecol. 24(4), 382-386 (2004).
134. Mecacci F, Carignani L, Cioni R et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. Eur. J. Obstet. Gynecol. Reprod. Biol. 111(1), 19-24 (2003).
135. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with Type 1 and Type 2 diabetes. Diabetes Care 25(5), 876-882 (2002).
136. Pettitt DJ, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care 26(1), 183-186 (2003).
137. Devlin JT, Hothersall L, Wilkis JL. Use of insulin glargine during pregnancy in a Type I diabetic woman. Diabetes Care 25(6), 1095-1096 (2002).
138. Holstein A, Plaschke A, Egberts EH. Use of insulin glargine during embryogenesis in a pregnant woman with Type 1 diabetes. Diabet. Med. 20(9), 779-780 (2003).
139. Zeszutek SL, Henderson CE, Machupalli S, Marcano H, O'Kane G. A descriptive study: long-acting analogue use in pregnancy. Obstet. Gynecol. 101(4), S35 (2003).
140. Dolci M, Mori M, Baccetti F. Use of glargine insulin before and during pregnancy in a woman with Type 1 diabetes and Addison's Disease. Diabetes Care 28, 2084-2085 (2005).
141. Di Cianni G, Volpe L, Lencioni C et al. Use of insulin glargine during the first weeks of pregnancy in five Type 1 diabetic women. Diabetes Care 28(4), 982-983 (2005).
142. Woolderink JM, van Loon AJ, Storms F, de Heide L, Hoogenberg K. Use of insulin glargine during pregnancy in seven Type 1 diabetic women. Diabetes Care. 28(10), 2594-2595 (2005).
143. Caronna S, Cioni F, Dall'Aglio E, Arsenio L. Pregnancy and the long-acting insulin analogue: a case study. Acta Biomed. 77(1), 24-26 (2006).
144. Graves DE, White JC, Kirk JK. The use of insulin glargine with gestational diabetes mellitus. Diabetes Care. 29(2), 471-472 (2006).
145. Cechurova D, Lacigova S, Jankovec Z et al. The insulin analog glargine during an unplanned pregnancy. Wien Klin. Wochenschr. 118(19-20), 619-620 (2006).
146. Torlone E, Gennarini A, Ricci NB, Bolli GB. Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women. Eur. J. Obstet. Gynecol. Reprod. Biol. 132(2), 238-923 (2007).
147. Price N, Bartlett C, Gillmer M. Use of insulin glargine during pregnancy: a case-control pilot study. Br. J. Obstet. Gynecol. 114(4), 453-457 (2007).